C5a, But Not C3a, Increases VEGF Secretion in ARPE-19 Human Retinal Pigment Epithelial Cells

REFERENCES

• Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38: 175–187
   PubMed Web of Science ®Google Scholar
• Pellas T C, Wennogle L P. C5a receptor antagonists. Curr Pharm Des 1999; 5: 737–755
   PubMed Web of Science ®Google Scholar
• Holland M C, Morikis D, Lambris J D. Synthetic small-molecule complement inhibitors. Curr Opin Invest Drugs 2004; 5: 1164–1173
   PubMedGoogle Scholar
• Guo R F, Ward P A. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821–852
   PubMed Web of Science ®Google Scholar
• Hageman G S, Anderson D H, Johnson L V, Hancox L S, Taiber A J, Hardisty L I, Hageman J L, Stockman H A, Borchardt J D, Gehrs K M, Smith R J, Silvestri G, Russell S R, Klaver C C, Barbazetto I, Chang S, Yannuzzi L A, Barile G R, Merriam J C, Smith R T, Olsh A K, Bergeron J, Zernant J, Merriam J E, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227–7232
   PubMed Web of Science ®Google Scholar
• Hageman G S, Hancox L S, Taiber A J, Gehrs K M, Anderson D H, Johnson L V, Radeke M J, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M. AMD Clinical study group. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution, and evolutionary implications. Ann Med 2006; 38: 592–604
   PubMed Web of Science ®Google Scholar
• Yates J R, Sepp T, Matharu B K, Khan J C, Thurlby D A, Shahid H, Clayton D G, Hayward C, Morgan J, Wright A F, Armbrecht A M, Dhillon B, Deary I J, Redmond E, Bird A C, Moore A T. Genetic factors in AMD study group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553–561
   PubMed Web of Science ®Google Scholar
• Ambati J, Anand A, Fernandez S, Sakurai E, Lynn B C, Kuziel W A, Rollins B J, Ambati B K. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 2003; 9: 1390–1397
   PubMed Web of Science ®Google Scholar
• Nozaki M, Raisler B J, Sakurai E, Sarma J V, Barnum S R, Lambris J D, Chen Y, Zhang K, Ambati B K, Baffi J Z, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006; 103: 2328–2333
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U M, Richard G, Augustin A, Aylward W G, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann R O. European Society for Retina Specialists' Guidelines Committee (EURETINA). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007; 85: 486–494
   PubMedGoogle Scholar
• Witmer A N, Vrensen G F, Van Noorden C J, Schlingemann R O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1–29
   PubMed Web of Science ®Google Scholar
• Ambati B K, Nozaki M, Singh N, Takeda A, Jani P D, Suthar T, Albuquerque R J, Richter E, Sakurai E, Newcomb M T, Kleinman M E, Caldwell R B, Lin Q, Ogura Y, Orecchia A, Samuelson D A, Agnew D W, St Leger J, Green W R, Mahasreshti P J, Curiel D T, Kwan D, Marsh H, Ikeda S, Leiper L J, Collinson J M, Bogdanovich S, Khurana T S, Shibuya M, Baldwin M E, Ferrara N, Gerber H P, De Falco S, Witta J, Baffi J Z, Raisler B J, Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993–997
   PubMed Web of Science ®Google Scholar
• Brodbeck R M, Cortright D N, Kieltyka A P, Yu J, Baltazar C O, Buck M E, Meade R, Maynard G D, Thurkauf A, Chien D S, Hutchison A J, Krause J E. Identification and characterization of NDT 9513727, a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther 2008, Aug 27 [epub]
   PubMed Web of Science ®Google Scholar
• Szallasi A, Blumberg P M, Annicelli L L, Krause J E, Cortright D N. The cloned rat vanilloid receptor VR1 mediates both R-type binding and C-type calcium response in dorsal root ganglion neurons. Mol Pharmacol 1999; 56: 581–587
   PubMed Web of Science ®Google Scholar
• Ames R S, Li Y, Sarau H M, Nuthulaganti P, Foley J J, Ellis C, Zeng Z, Su K, Jurewicz A J, Hertzberg R P, Bergsma D J, Kumar C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996; 271: 20231–20234
   PubMed Web of Science ®Google Scholar
• Slomiany M G, Rosenzweig S A. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol 2004; 287: C746–753
   PubMed Web of Science ®Google Scholar
• Fukuoka Y, Medof E M. C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res 2001; 23: 320–325
   PubMed Web of Science ®Google Scholar
• Fukuoka Y, Strainic M, Medof M E. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol 2003; 131: 248–253
   PubMed Web of Science ®Google Scholar
• Richards A, Kavanagh D, Atkinson J P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007; 96: 141–177
   PubMed Web of Science ®Google Scholar
• Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets 2007; 11: 625–639
   PubMed Web of Science ®Google Scholar
• Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade M B, Brodbeck R M, Krause J E, Choe H R, Gerard N P, Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003; 42: 9406–9615
   PubMed Web of Science ®Google Scholar
• Maslowska M, Legakis H, Assadi F, Cianflone K. Targeting the signaling pathway of acylation stimulating protein. J Lipid Res 2006; 47: 643–652
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl M A, Nadeau B A, Day D E, Huber-Lang M, Mackay C R, Zetoune F S, Gerard N P, Cianflone K, Köhl J, Gerard C, Sarma J V, Ward P A. Functional roles for C5a receptors in sepsis. Nat Med 2008; 14: 551–557
   PubMed Web of Science ®Google Scholar
• Sumichika H. C5a receptor antagonists for the treatment of inflammation. Curr Opin Invest Drugs 2004; 5: 505–510
   PubMedGoogle Scholar
• Monk P N, Scola A M, Madala P, Fairlie D P. Function, structure, and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429–448
   PubMed Web of Science ®Google Scholar